Index

AA. See Alcoholics Anonymous
AAT. See Appetite awareness training
Abandonment, fear of, 563
Abbott, M. J., 160–161
Abelson, J. L., 106, 108
Abnormal Involuntary Movement Scale (AIMS), 414, 415
Abraham, K., 263
Abelson, J. L., 106, 108
Abbott, M. J., 160–161
Abandonment, fear of, 563
AA. See Alcoholics Anonymous
INDEX

At-risk mental states (ARMS), 411
Attachment
with panic disorder, 97–98
with social anxiety disorder, 56
theory, 579
Attention bottleneck, 629
Attention Network Task (ANT), 581–582
Attentional bias, 49–51
Attention-deficit/hyperactivity disorder (ADHD), 322, 323
Attention-intention-effort pathway, 372
Attenuation paradox, 24–25
Autism spectrum disorder, 23
Autobiographical Memory Test (AMT), 583
Automatic thoughts, 273–274
Autonomic nervous system, 106–108
Autonomic rigidity, 156
Aviation
with agoraphobia, 91
assessments of, 204
cognitive avoidance model, 160–161
contrast avoidance model, 161
experiential, 93–94
interoceptive, 91–92
with major depressive disorder, 272–273
with obsessive-compulsive disorder, 190–191
with panic disorder, 91–92
passive avoidance task, 581
with posttraumatic stress disorder, 231–232
with social anxiety disorder, 62
theories of worry, 160–161
Avoidant personality disorder (APD), 45
Avolition, 394–395

Beck Depression Inventory-II, 61, 291–292
Beck Hopelessness Scale, 292
Beck’s cognitive model
automatic thoughts, 273–274
cognitive distortions, 274–275
core beliefs, 275
BED. See Binge eating disorder
Behavior therapy (BT), 477
Behavioral activation system (BAS), 22, 625, 626
Behavioral activation (BA) therapy, 245, 294
Behavioral genetics, 448
Behavioral inhibition, 55, 581
Behavioral inhibition system (BIS), 272, 273, 625–626, 627
Behavioral marital therapy (BCT), 450
Behavioral sensitization, 327
Behavioral weight loss (BWL), 499
Beliefs, dysfunctional, 197
Benito, K., 55
Benzodiazepine receptor agonists (BzRAs), 380–381
Benzodiazepines
alprazolam, 65
bromazepam, 65
clonazepam, 65
for generalized anxiety disorder, 154, 172, 173
Klonopin, 88
for panic disorder, 120, 121
for posttraumatic stress disorder, 244
sensitivity to, 106
for sleep-wake disorders, 381
for social anxiety disorder, 65
BEP. See Brief eclectic psychotherapy
Berksonian bias, 22
Bernardy, Friedman, 244
Bertsch, K., 575
Bezdjian, S., 633
BFNE. See Brief Fear of Negative Evaluation scale
BFNE-S, 60
Biedert, E., 499
Binge eating disorder (BED), 465
appetite awareness training for, 494
bulimia nervosa and, 478
case example, 479–480
comorbidity, 483
course, 482–483
cultural norms supporting, 476
diagnostic criteria, 477–478
in DSM-5, 468, 477
emotional regulation, 477, 499
medical problems with, 479
neurobiology, 484, 485
objective binge episodes, 478
prevalence, 481
transdiagnostic model, 477
treatment, 498
CBT for eating disorders, 493
cognitive-behavioral therapy, 499
in-patient, day hospital, and residential treatments, 500–501
interpersonal psychotherapy, 499
INDEX

psychopharmacological and biological interventions, 501–502
self-help, 499–500
weight, 478, 487, 499
Blair, K. S., 627, 628
Blanco, C., 269
Blechert, J., 110
Bonomi, D. M., 632, 633, 634
Body mass index (BMI), See Bulimia nervosa
Body Checking Questionnaire, 491
Body dysmorphic disorder (BDD), 193, 398
Body mass index (BMI), 469, 471, 486, 487
Body Sensations Questionnaire, 113
Body surveillance, 486
den Boer, J. A., 572–573
Blonigen, D. M., 632, 633, 634
Blechert, J., 110
Body Sensations Questionnaire, 113
Body mass index (BMI), 469, 471, 486, 487
Body Sensations Questionnaire, 113
Body surveillance, 486

BIPD. See Borderline personality disorder
BPI. See Borderline Personality Inventory

Brain-derived neurotrophic factor (BDNF) gene, 283, 284, 286

Bowlby, J., 97, 579
Bozarth, M. A., 447
BPD. See Borderline personality disorder
BPI. See Borderline Personality Inventory

Bradykinesia, 415

Brain-derived neurotrophic factor (BDNF) gene, 283, 284, 286

Brandsma, L. L., 59
Bremner, J. D., 225
Brewin, C. R., 227, 233

Brief eclectic psychotherapy (BEP), 241–242
Brief Fear of Negative Evaluation scale (BFNE), 59, 60
Brief psychotic disorder, 398
Brietzcke, E., 328
Brink, D., 381–382
van den Brink, W., 572–573
Brinkley, C. A., 622
Bromazepam, 65
Bromet, E., 572–573
Brown, G., 330
Brown, T. A., 58, 221–222, 466
Brown Assessment of Beliefs Scale (BABS), 200
Bruch, Hilde, 467
Bryant, R. A., 240

BT. See Behavior therapy; Individual behavior therapy

Buhro, K., 161
Buie, D. H., Jr., 568
Bulimia nervosa (BN), 465
appetite awareness training for, 494
binge eating disorder and, 478
binge/purge episodes, 473–474, 475
case example, 479–480
comorbidity, 478, 483
course, 482–483
diagnostic models of, 473
in DSM-5, 468
in DSM-III-R, 472
in DSM-IV, 473
history of, 472–473
laxative abuse with, 475
medical complications, 475
prevalence, 480–481
relapse, 482
treatments
CBT for eating disorders, 493, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497
cognitive-behavioral therapy, 473, 497

Bulimia Test-Revised, 491
Bupropion, 338, 523, 527, 532
Bureau of the Census, U.S., 15–16
Burgess, D., 3

Blair, K. S., 627, 628
Blanco, C., 269
Blashfield, R., 3
Blechert, J., 110
Blomgren, D. M., 632, 633, 634

Body mass index (BMI), 469, 471, 486, 487
Body mass index (BMI), 469, 471, 486, 487
Body mass index (BMI), 469, 471, 486, 487
Body mass index (BMI), 469, 471, 486, 487

Borderline Personality Inventory (BPI), 589
Borkovec, T. D., 163, 166

Boskind-Lodahl, M., 472
Boullosa (hunger), 472
Bouton, M. E., 101, 110, 111

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

(Continued)

posttraumatic stress disorder, 217–218, 221
premature (early) ejaculation, 545–546
schizophrenia, 396–397
sexual dysfunctions, 520, 521, 529, 542–543, 549–550
sleep disorders, 516
social anxiety disorder, 39–40
sociopathy, 614–615
stimulant use disorder, 435
tobacco use disorder, 435
Diagnostic Interview for Personality Disorders (DIPD-IV), 587
Diagnostic Interview Schedule (DIS), 236
Diagnostic overshadowing, 22
Dialectical behavior therapy (DBT), 494, 497, 593–594
Diathesis-Stress model
definition of, 289
with depression, 275, 287
with panic disorder, 101, 102, 103
for schizophrenia, 412–413
DIB-R. See Revised Diagnostic Interview for Borderlines
Dicker, S., 498
Dickstein, B. D., 230–231
Dieting, 486
Differential diagnosis, 4
Diffusion tensor imaging (DTI), 406, 576
Dimensional approach, 25–28
Dimensional Obsessive-Compulsive Scale (DOCS), 202
Dimidjian, S., 294
Dinges, D. F., 372
DIPD-IV. See Diagnostic Interview for Personality Disorders
Directed forgetting task, 581
Directed masturbation (DM), 541–542
DIS. See Diagnostic Interview Schedule
Diseases, 3
Disorientation, left-right, 2
Disruptive mood dysregulation disorder, 23
Distraction, 93
Distressing Event Questionnaire (DEQ), 236
Disulfiram, 451
Divalproex
with bipolar disorder, 322, 337–338
with borderline personality disorder, 593
with posttraumatic stress disorder, 244
Dizygotic (DZ) twins, 402, 405
DLPFC. See Dorsolateral prefrontal cortex
DM. See Directed masturbation
DOCS. See Dimensional Obsessive-Compulsive Scale
Dodson, M. C., 635
Doehrmann, O., 61
Domes, G., 582
Dopamine
with bipolar disorder, 327, 331
with borderline personality disorder, 571, 573
with eating disorders, 484
with posttraumatic stress disorder, 225, 413
with schizophrenia, 407–408, 410, 413, 415, 446, 447
with social anxiety disorder, 47
Dopamine transporter gene (DAT1), 571
Dorsolateral prefrontal cortex (DLPFC), 576
Dot-probe task, 49–50, 159
Drinking cultures, 439
Drug, concept of, 15
Drye, R., 565
DSPT. See Delayed sleep phase test
DST. See Dexamethasone suppression test
DTI. See Diffusion tensor imaging
Duffy, A., 325
Dugas, M. J., 161, 162
Duloxetine, 173, 532
Dunmore, E., 230
van Dyck, R., 592
DZ. See Dizygotic twins
EAPs. See Employee Assistance Programs
Eating Disorder Examination (EDE), 490–491
Eating Disorder Inventory (EDI), 491
Eating Disorders Assessment for DSM-5
Eating Disorders Assessment for DSM-5
EDE. See Eating Disorder Examination
EDE-Q, 491
with EDI-3. See Eating Disorder Inventory
Edronax. See Reboxetine
EDS. See Eating disorders
EE. See Expressed emotion
EEG. See Electroencephalogram
Effexor. See Venlafaxine
Effort syndrome, 87
Ego-dystonic, 13, 194
Ego-syntonic, 13, 194
Ehlers, A., 227, 230
Ehlers, C. L., 331
Eifert, G. H., 118
Eisler, L., 495
Electroconvulsive therapy (ECT), 296
Electroencephalogram (EEG), 95–96, 401
Electromyographic biofeedback, 553
Elemental Psychopathy Assessment (EPA), 623
Ellicott, A., 330
Elwood, L. S., 240
EMA. See Ecological momentary assessment
EMDR. See Eye movement desensitization and reprocessing
Emotional involvement (EIO), 591–592
Emotional reasoning, 275
Emotionally unstable disorder, 565
Employee Assistance Programs (EAPs), 430–431
Employment, impairment in, 41
Endicott, J., 565
Endocrines, 523
Endophenotype approach, 28–29
Endophenotypes, 5, 448
Eng, W., 152
EOL. See Emotional overinvolvement
EPA. See Elemental Psychopathy Assessment
Epigenetics, 404–405
Epinephrine challenge, 94, 95
EPSI. See Eating Pathology Symptoms Inventory
Epstein, D., 377
Erectile disorder (ED) assessment, 535
biological factors, 533–534
definition, diagnosis, and prevalence, 533
in DSM-5, 533
psychological factors, 534–535
treatment, 535–537
EROS clitoral therapy device, 528
ERP. See Exposure and response prevention
Erwin, B. A., 43, 54
Escitalopram, 173
ESEMeD. See European Study of the Epidemiology of Mental Disorders
Espie, C. A., 372, 378
Estrogen, 489, 490, 522, 523, 526–527, 553
European Medicines Agency, 527
European Study of the Epidemiology of Mental Disorders (ESEMeD), 41
Evaluation, fear of, 48
Ex juvantibus reasoning (reasoning backward from what works), 4–5
Exercise, compulsive, 469
Exercise anorexia, 470
Exophenotypes, 5
Expectancy theory, 442–443
Experiential avoidance, 93–94
Exposure and response prevention (ERP), 205–208, 209
Expressed emotion (EE), 330, 591
Extrapyramidal symptoms, 415
Eye movement desensitization and reprocessing (EMDR), 241
Eysenck, H. J., 110

FA. See Functional anisotropy
Facial masking, 415
Factorial validity, 6
Fairburn, C. G., 473, 499
Family-based treatment (FBT), 495–496, 497–498
Family-focused treatment (FFT), 341–343, 347
Fava, G. A., 117
FBT. See Family-based treatment
FBT for adolescent BN (FBT-BN), 498
FDA. See Food and Drug Administration
Fearlessness, 625, 626–627
Fear-potentiated startle (FPS), 630
Feighner criteria, 17, 432
Feinstein, A. R., 22
Female orgasmic disorder (FOD) assessment, 541
biological factors, 538–539
definition, diagnosis, and prevalence, 537–538
in DSM-5, 537
psychological factors, 540–541
treatment, 541–542
Female sexual arousal disorder (FSAD), 521
Female Sexual Function Index (FSFI), 523
Female sexual interest/arousal disorder (FSIAD) assessment, 526
biological factors, 522–524
definition, diagnosis, and prevalence of, 521
EROS clitoral therapy device for, 528
psychological factors, 524–525
treatment, 526–528
Fergus, T. A., 157
Fernandez, K. C., 59
Ferster, C. B., 271
Fertuck, E. A., 582, 584–585
Feuer, C. A., 239
FFM. See Five-factor model
FFS. See Fight/flight system
FFT. See Family-focused treatment
Fichtner, C., 225
Field, A. P., 171
Fight/flight system (FFS), 625
Finger, E. A., 628
Finger agnosia, 2
Fischer, L., 59
Fitzgerald, H. E., 443
Fitmaurice, G., 590, 591
5-HIAA. See 5-Hydroxyindoleacetic acid
5-HT. See Serotonin
5-HTTLPR. See Serotonin gene polymorphism

INDEX

5-Hydroxyindoleacetic acid (5-HIAA), 285, 572
Five-factor model (FFM), 26–28, 586, 588–589, 622–623
FKBP5. See Glucocorticoid receptor chaperone protein gene
Flibanserin, 527
Fluoxetine
with bipolar disorder, 339
with borderline personality disorder, 577
with bulimia nervosa, 501, 502
with posttraumatic stress disorder, 245
with sexual dysfunctions, 539, 548
with social anxiety disorder, 64–65
Fluvoxamine, 64, 592
fMRI. See Functional magnetic resonance imaging
FOD. See Female orgasmic disorder
Fonagy, P., 566–567, 579, 594
Food and Drug Administration (FDA), U.S., 451, 526
Ford, D. E., 368
Fowles, D. C., 626
FPS. See Fear-potentiated startle
Frances, Allen, 23
Frank, E., 344
Frankenburg, F. R., 562, 567, 590, 591, 593
Franklin, M. E., 165
Freeman, A., 470
Freeman, J. B., 200
Freeston, M. H., 165
Freeman, A., 470
Franklin, M. E., 165
Friedan, R. O., 573
Friedman, B. H., 156
FSAD. See Female sexual arousal disorder
FSFI, 523
FSIAD. See Female sexual interest/arousal disorder
5-Hydroxyindoleacetic acid (5-HIAA), 285, 572
Five-factor model (FFM), 26–28, 586, 588–589, 622–623
FKBP5. See Glucocorticoid receptor chaperone protein gene
Flibanserin, 527
Fluoxetine
with bipolar disorder, 339
with borderline personality disorder, 577
with bulimia nervosa, 501, 502
with posttraumatic stress disorder, 245
with sexual dysfunctions, 539, 548
with social anxiety disorder, 64–65
Fluvoxamine, 64, 592
fMRI. See Functional magnetic resonance imaging
FOD. See Female orgasmic disorder
Fonagy, P., 566–567, 579, 594
Food and Drug Administration (FDA), U.S., 451, 526
Ford, D. E., 368
Fowles, D. C., 626
FPS. See Fear-potentiated startle
Frances, Allen, 23
Frank, E., 344
Frankenburg, F. R., 562, 567, 590, 591, 593
Franklin, M. E., 165
Freeman, A., 470
Freeman, J. B., 200
Freeston, M. H., 165
Freud, Sigmund, x, 194, 263
Friedel, R. O., 573
Friedman, B. H., 156
FSAD. See Female sexual arousal disorder
FSFI, 523
FSIAD. See Female sexual interest/arousal disorder
Functional anisotropy (FA), 406
Functional magnetic resonance imaging (fMRI)
with anorexia nervosa, 484
with panic disorder, 328, 406, 443
Furmark, T., 46
Fusiform cortex, 46
GABA. See Gamma-aminobutyric acid
Gabapentin, 65
GAD. See Generalized anxiety disorder
GAD-7. See General Anxiety Disorder 7-Item Scale
GADQ-IV. See General Anxiety Disorder Questionnaire for DSM-IV
Galen, 263, 472
Gallagher, M. W., 230
Gallus, K., 347
Gallop, R., 166
Galvovski, T. E., 232, 240
Gamma, A., 322
Gamma-aminobutyric acid (GABA) with alcohol use disorder, 447, 452
with generalized anxiety disorder, 154
with panic disorder, 105–106
with posttraumatic stress disorder, 225
with sleep-wake disorder, 380
Gaon, S. Y., 550
Garber, A. K., 500
Garcia, A. M., 200
Gardenswartz, C. A., 122
GBI. See General Behavior Inventory
Geddes, J. R., 339
General Behavior Inventory (GBI), 293, 336
General psychiatric management (GPM), 595
Generalized anxiety disorder (GAD) assessment
ADIS-5, 167
criteria, 166
ongoing and follow-up, 169
SCID-5, 167
cognitive and behavioral correlates avoidance theories of worry, 160–161
information processing biases in worry, 158–160
intolerance of uncertainty, 161–162
life events, 156–157
metacognition, 162–164
probability overestimation and catastrophizing, 158
problem-solving ability, 157–158
comorbidity, 152, 153
in DSM-5, 149–150
in DSM-III-R, 149, 150–151
e emotional correlates, 164–165
environmental and family factors, 165–166
gender differences, 152
historical perspectives on, 150–151
neurobiology, 153–155
prevalence and epidemiological factors, 151–153
prevention, 175
psychopathology, 155–156
self-report measures
Generalized Anxiety Disorder 7-Item Scale, 168
Generalized Anxiety Disorder Questionnaire, 168
purposes of, 167
theoretical constructs, 168–169
worry, severity and content, 168
summary and new directions, 174–175
symptoms and diagnostic criteria, 149–150

treatment
biological interventions, 172–174
cognitive-behavioral therapy for, 163, 170–172
psychological interventions, 169–172
Generalized Anxiety Disorder 7-Item Scale (GAD-7), 168
Generalized Anxiety Disorder Questionnaire for DSM-IV (GADQ-IV), 168
Genito-pelvic pain/penetration disorder (GPPPD) assessment, 552–553
biological factors, 550–551
definition, diagnosis, and prevalence, 549–550
in DSM-5, 549–550
Genito-pelvic pain/penetration disorder

(Continued)

psychological factors, 551–552

treatment, 553–554

Genome-wide association studies (GWAS), 283, 489, 572

Gerber-Werder, R., 322

Gerstmann’s syndrome, 2

GES. See Good Enough Sex model

Gibbon, M., 565

Gibbons, M. B. C., 466

Gieson-Bloo, J., 595

Gilman, R., 230

Gitlin, M., 330

Glazer, H. I., 553

Globulin, 523

Gloster, A. T., 119

Glostone, P. B., 369

Glucocorticoid receptor chaperone protein

Glucocorticoid receptor protein

Glover, P. B., 369

Gotlib, I. H., 280

Götestam, K. G., 209

Gorwood, P., 571

Gorenstein, E. E., 15

Gordon, I., 485

Gordon, E. A., 48

Gordon, D., 167

Grosscup, S. J., 294

Group augmentation, 539

Guanfacine, 244

Gueorguieva, R., 499

Gull, W., 466–467

Gunderson, J. G., 565, 567

Gunnar, M., 98

Gupta, B. P., 537

Guze, S. B., 4, 5, 6, 24

GWAS. See Genome-wide association studies

Hackett, A., 533

Hadjistavrou, L., 408

Hajek, T., 325

Hall, J., 585

Hallucinations, 393

HAM-D. See Hamilton Rating Scale for Depression

Hamilton, R. K. B., 628–629

Hamilton Rating Scale for Depression (HAM-D), 292, 293

Hammen, C., 330

Hanrahan, F., 171

Hare, R. D., 615, 617, 621–622

Harkness, A. R., 26

Harlow, B. L., 552

Harm-reduction models, 431

Harris, G. T., 635

Harte, C. B., 534–535

Harvey, A. G., 383

Haslam, N., 586

Hautzinger, M., 343–344

Hay, P., 480

Hayes, S. A., 61

Hayes, S. C., 119, 172

Hazlett, E. A., 576

Heart rate, variability of, 107, 156, 524

Hecht, K. F., 572

Hedges, D. W., 226

Heimberg, R., 46

Heimberg, R. G., 48, 49, 59–60, 63, 152, 167

Hengeveld, M. W., 547

Hennen, J., 567

Herbert, J. D., 59

Herman, C. P., 443

Herpertz, S. C., 575

Hertz, R., 553

Herzog, D. B., 482

Hettema, J. M., 155

Hetzl, S., 572

Hillatt-Racer, K., 628–629

Hicks, B. M., 632

Highly behavioral exposure therapy, 495

Hinckley, John, 9

Hinton, D., 41

Hippocampus, 225, 226, 406, 575, 576

Hippocrates, 263, 318

Hirsch, C., 55

Hoarding, 193–194

Hobfoll, S. E., 234

Hoffman, P. D., 591

Hoffman, S. A., 41, 42

Hoffman, S. G., 43

Hoge, C. W., 221

Holland, L. A., 466

Hollander, E., 573

Homosexuality, 12

Hong, L. K., 546

Hooley, J., 582

Hooley, J. M., 584, 591

Hopelessness theory of depression, 276–277

Hormones

adrenocorticotropic hormone, 224, 287, 288, 574

androgens, 522, 523, 526

cortisol, 154–155, 224, 413, 573–574

estrogen, 489, 490, 522, 523, 526–527, 553

oxytocin, 47, 539, 545, 571–572, 575

testosterone, 489

thyrotropin, 547

Hovland, A., 120

Hove, M., 347

HPS. See Hypomanic Personality Scale

HSDD. See Hypoactive sexual desire disorder

Hudson, J., 99

Hudson, J. L., 165

Hughes, M., 220

Hymenoplasty, 539

Hyperprolactinemia, 530, 532

Hypersomnia, 383

Hypothyroidism, 532, 547

Hypervigilance, 51

Hypnics, 380

Hypoactive sexual desire disorder (HSDD), 521

Hypochondriasis, 96

Hypogonadism, 530, 531

Hypomanic episodes, 318

Hypomanic Personality Scale (HPS), 336

Hypothalamic-pituitary-adrenal (HPA) axis with borderline personality disorder, 573–574

functional organization, 287

with generalized anxiety disorder, 154, 155

with major depressive disorder, 286–288

with panic disorder, 106–108

pathophysiology, 287–288

with posttraumatic stress disorder, 224–225

with schizophrenia, 413

Hypothalamo-hypophyseal portal system, 287

Hypothyroidism, 530, 532

Iacono, W. G., 632, 633

ICAT. See Integrative Cognitive-Affective Therapy

ICD-10. See International Classification of Diseases, 10th edition

ICL. See Individual clinical management

ICSD-3. See International Classification of Sleep Disorders

Identity disturbance, 563

IES-R. See Impact of Event Scale-Revised

IFNγ. See Interferon gamma

III. See Interpretations of Intrusions Inventory

IIIT. See Impaired integration theory

IL-4. See Interleukin-4

Imagery rescripting, 245

Immigrant paradox, 438

Impact of Event Scale-Revised (IES-R), 236

Impaired integration theory (IIT), 628–629

Implicit memory, 53, 159

Improving Access to Psychological Therapies, 300

Impulsivity, 445, 563, 570

In-Albon, T., 43

Incentive salience, 448

Individual behavior therapy (BT), 379

Individual clinical management (ICL), 344

INDEX
### Index

| Page 659 |
|-----------------|------------------|
| Inflammation, 288–289, 328, 576 | Jimenez, S., 241 |
| Influenza (flu), 14 | Johnson, J. G., 578 |
| Information retrieval, 3 | Johnson, S. L., 334 |
| Inhibitory deficits, 196 | Johnson, V. E., 528, 536–537, 546, 547 |
| Insel, Thomas, 10 | Jones, B., 583 |
| Insomnia. See Sleep-wake disorders | Jones, C., 229 |
| Insula, 46 | Jones, F., 171 |
| Integrative Cognitive-Affective Therapy (ICAT), 497 | Joormann, J., 280 |
| Intelligence, assessment of, x | Jouriles, E. N., 635 |
| Intensive outpatient programs (IOPs), 501 | Joyce, P. R., 571 |
| Intercorrelation coefficient, 9–10, 16, 17, 18 | Judgment and interpretation bias, 51–53, 55 |
| Internal validation, 6 | Kabat-Zinn, J., 119 |
| International Classification of Diseases, 10th edition (ICD-10), 20–21 diagnoses in, 1, 433 | Kamerow, D. B., 547 |
| emotionally unstable disorder in, 565 | Kaplan, H. S., 547 |
| International Consultation on Urological Diseases in Official Relationship with the World Health Organization, 538 | Kaplan, M. H., 22 |
| International Personality Disorder Examination (IPDE), 587 | Kappa coefficient, 9 |
| International Research Group on Gender and Alcohol, 438–439 | Karpman, B., 25 |
| Interceptive awareness, 486 | Kazdin, A. E., 2 |
| Interceptive conditioning, 110–111 | Kean, Y., 41 |
| Interpersonal and social rhythm therapy (IPSRT), 344, 384 | Keane-PTSD Scale (PK), 237 |
| Interpersonal psychotherapy (IPT), 295, 298, 496, 497 | Keel, P. K., 466, 489 |
| Interpretation bias. See Judgment and interpretation bias | Kegeles exercises, 541, 542 |
| Interpretations of Intrusions Inventory (II), 203 | Kendall, P. C., 165 |
| Interrater reliability, 9–10, 16, 17, 18 | Kennedy, R., 278 |
| Intolerance of Uncertainty Scale, 169 | Keough, M. E., 122 |
| Intracavernosal injections, 536 | Keri, S., 585 |
| Intraclase correlation coefficient, 9 | Kernberg, Otto, 137, 582, 594 |
| Invalidation, 569 | Kessing, L. V., 341 |
| Involuntary memory, 53 | Keri, S., 585 |
| IOPs. See Intensive outpatient programs | Kernofsky, M., 328, 332–333 |
| IPDE. See International Personality Disorder Examination | Kindling, 333 |
| Ipecac, 476 | Kingsberg, S. A., 549 |
| Iproniazid, 284 | Klein, D. F., 87 |
| IPSRT. See Interpersonal and social rhythm therapy | Klein, D. N., 268, 282, 299 |
| IPT. See Interpersonal psychotherapy | Klingberg, T., 636 |
| Ivers, H., 373 | de Kloet, R., 574 |
| Iverson, K. M., 240 | Klonopin, 88 |
| Jacobson, N. S., 294 | Klump, K. L., 573 |
| James, P., 472 | Koerner, N., 162 |
| James, William, 262 | Kohut, Heinz, 568, 569 |
| Jamison, K., 330 | Koplik’s spots, 19–20 |
| Janssen, E., 525 | Korff, L., 582 |
| Jardi, R., 571 | Koro, 20 |
| Jester, J. M., 443 | Kotov, R., 268 |
| K-lifetime. See Schizophrenia, Present and Lifetime Version (K-SADS-PL), 335 | Kraepelin, Emil, x, 17, 263, 612 |
| K-SADS-PL. See “Kiddie” Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version | Kreuger, R. F., 632 |
| Kubany, E. S., 230 | Kupfer, David, 20 |
| Kushner, M. G., 44 |
| Labeling theory, 11–12 | Labels, 10 |
| Labiaplasty, 539 | Laderocquet, R., 161, 165 |
| Lam, D. H., 343, 344 | Lamottegnine, 244, 339, 593 |
| Lang, P. J., 232 | Langlois, F., 165 |
| Larsson, H., 632, 633 | Lask, B., 485 |
| Latuda. See Lisdexamfetamine dimesylate | Latuda. See Lisdexamfetamine dimesylate |
| Learned helplessness theory, 276 | Lecakman, E. O., 540, 546 |
| LEC-5. See Life Events Checklist for DSM-5 | Lauenbacher, S., 95 |
| Laxatives, abuse of, 475 | Lessivals, 231, 294 |
| LDX. See Lisdexamfetamine dimesylate | Lewis, A., 617 |
| Lesions, 7–8 | LHPA. See Limbic-hypothalamic-pituitary-adrenal axis |
| Lichteinstein, P., 632 | Lidell, H. G., 472 |
| Lidocaine, 548 | Lieb, K., 574 |
| Liebowitz Social Anxiety Scale (LSAS), 58–59 | Liefeld, J., 341 |
| LIJE. See Longitudinal Interval Follow-up Evaluation | Levinson, M. R., 622 |
| Limb, K., 341 | Lewinsohn, P. M., 271, 294 |
| Limbic-hypothalamic-pituitary-adrenal (LHPA) axis, 154 | Lewis, A., 617 |
| Lincoln, Abraham, 262 | Lidell, H. G., 472 |
| Linehan, M. M., 172, 566, 568–569, 593 | Liebe, K., 574 |
| Linnaeus, Carl, 1 | Liebowitz Social Anxiety Scale (LSAS), 58–59 |
| Lisdexamfetamine dimesylate (LDX), 502 | LIJE. See Longitudinal Interval Follow-up Evaluation |
| Lithium | Life Events Checklist for DSM-5 (LEC-5), 235 |
| for bipolar disorder, 322–323, 325, 328, 337, 338, 339 | Limb, K., 341 |
| for borderline personality disorder, 593 | Limbic-hypothalamic-pituitary-adrenal (LHPA) axis, 154 |
| Llera, S. G., 161 | Lock, J., 494 |
| Lock, J., 494 | Loevinger, J., 23 |
| Loftus, J., 521 | Long, J. S., 521 |
| Loney, B. R., 278 | Longitudinal Interval Follow-up Evaluation (LIJE), 291, 336–337 |
| Lorenz, T. A., 524 | |
INDEX

663

Passive avoidance task, 581
Paterson, L. Q., 550
Pathogenetic comorbidity, 22
Pathognomonic indicator, 19
Patient Health Questionnaire (PHQ-9), 292
Patient Outcomes Research Team (PORT), 417
Patrick, C. J., 632
Paulhus, D. L., 624
Pauli, P., 96
Pause technique, 548
Paxil. See Paroxetine
PBRS. See Personal Beliefs and Reactions Scale
PCIT. See Parent-child interaction therapy
PCL: Screening Version (PCL:SV), 619, 620
PCL: Youth Version (PCL:YV), 619–620
PCL-5. See Posttraumatic Diagnostic Scale
PCL-R. See Psychopathy Checklist-Revised
PCL:SV. See PCL: Screening Version
PCL:YV. See PCL: Youth Version
PCP. See Phencyclidine
PCT. See Panic control treatment; Present-centered therapy
PDD. See Persistent depressive disorder
PDE-5 inhibitors, 527, 535, 536, 537, 548
PDEs. See Phosphodiesterases
PDI-IV. See Personality Disorder Interview
PDQ-4. See Personality Disorders Questionnaire
PDS-5. See Posttraumatic Diagnostic Scale for DSM-5
PDSR. See Panic Disorder Self-Report
PDSS. See Panic Disorder Severity Scale
PE. See Premature (early) ejaculation; Prolonged exposure
Pearson correlation coefficient, 9
Peer victimization, 56–57
Penile implants, 536
Penn State Worry Questionnaire, 168
PEP. See Post-event processing
PER 3. See Period circadian clock 3
Perelman, M. A., 534
Performance anxiety, 535
Periactin. See Cyproheptadine
Perineoplasty, 539
Period circadian clock 3 (PER3), 368–369
Periodic limb movement disorder (PLMD), 382
Perry, A., 341
Persistent depressive disorder (PDD), 262
assessment of, 292–293
diagnostic criteria for, 264, 266–267, 270
in DSM-5, 266–267
prevalence, 209
treatment
acute-phase treatment, 297–298
continuation and maintenance, 298–299
Personal Beliefs and Reactions Scale (PBRS), 230
Personality and Personality Disorders Work Group, 565
Personality Assessment Inventory (PAI), 588
Personality Assessment Inventory-Borderline Features (PAI-BOR), 589
Personality Disorder Interview (PDI-IV), 587
Personality disorders. See also specific personality disorders
comborbid with, 21–22
interrater reliability of, 10, 16
Personality Disorders Questionnaire (PDQ-4), 587
Personality Inventory for DSM-5 (PID-5), 27
Personality theory, 444–445
Personalization, 275
PET. See Positron-emission tomography
Peterson, C. B., 473
Phencyclidine (PCP), 408
Phenelzine, 65
Phentolamine, 536
Phosphodiesterases (PDEs), 535–536
PDQ-5. See Personality Inventory for DSM-5
Pimintel, S. I., 165
Pincus, A. L., 166
Pinel, P., 612–613
Pinto-Gouveia, J., 534
Pittsburgh Bipolar Offspring Study (BIOS), 322, 325
Pittsburgh Maintenance Therapies study, 344
Pituitary glands, 107
PK. See Keane-PTSD Scale
PLMD. See Periodic limb movement disorder
PMBS. See Posttraumatic Maladaptive Beliefs Scale
PNS. See Parasympathetic nervous system
Polysomnography (PSG), 376
Polychotomous approach, 19
Pope, M., 585
PORT. See Patient Outcomes Research Team
Positive and Negative Syndrome Scale
Positive symptoms, 393, 396
Positron-emission tomography (PET)
with alcohol use, 446–447
with bipolar disorder, 328
with borderline personality disorder, 576–577
with obsessive-compulsive disorder, 199
with eating disorders, 484
Posner, M. I., 581
Post-event processing (PEP), 49
Posttraumatic Diagnostic Scale for DSM-5 (PDS-5), 236
Posttraumatic Maladaptive Beliefs Scale (PMBS), 230
Posttraumatic stress disorder (PTSD), x, 54
assessment diagnostic interviews, 235–236
physiological assessment, 237
self-report measures, 236–237
traumatic events, 234–235
behavioral factors, 231–232
biological factors
brain structures, 225–226
dopamine, 225, 413
GABA, 225
HPA axis, 224–225
noradrenergic system, 223–224
serotonin, 225
borderline personality disorder with, 574
case example, 218–219
cognitive and environmental factors
cognitive disruption, 226–228
research on cognitive content, 229–231
research on cognitive processes,
228–229
comorbidity and personality, 221–223
diagnosis, 276–277
environmental factors
conservation of resources, 233–234
intimate relationships, 233
personally directed, 232–233
social support and additional life stress, 233
gender differences, 221
mood stabilizers and anticonvulsants, 244
prevalence and epidemiological factors, 219–221
psychopharmacological treatment
anxiolytics, 243–244
antidepressants, 243
augmentation with partial NMDA agonist, 244
GABA-ergic agonists, 244
psychosocial treatment
brief eclectic psychotherapy, 241–242
cognitive-behavioral conjoint therapy, 242, 245
cognitive-behavioral therapy, 238–241
drug treatment options, 241
eye movement desensitization and reprocessing, 241
narrative exposure therapy, 242
for younger patients, 242–243
summary and future directions, 246–247
symptoms and diagnostic criteria, 216–218
treatment summary, 245–246
PPI. See Psychopathic Personality Inventory
Prazosin, 243–244
Prefrontal cortex
with bipolar personality disorder, 328, 329, 331, 347
with borderline personality disorder, 576, 591
with social anxiety disorder, 46, 47
Pregabalin, 65, 173–174
Pregnancy, 14
Premature (early) ejaculation (PE) assessment, 548
biological factors, 546–547
definition, diagnosis, and prevalence, 545–546
in DSM-5, 545–546
psychological factors, 547
treatment, 548–549
Present-centered therapy (PCT), 239
PRL. See Psychopathy Resemblance Index
Price, M., 50–51
Prichard, J. C., 613
Priliming. See Dapoxetine
Prilocaine, 548
**INDEX**

Rational Recovery (RR), 430
Raymond, N. C., 473
RDC. See Research Diagnostic Criteria
RDoC. See Research Domain Criteria
Rea, M. M., 342, 344
Reality monitoring, 196
Reboxetine, 523
Receptive desire, 526
Regier, Darrel, 20
Reich, D. B., 590, 591
Relapse, 445–446
Relaxation therapy, 378
Religiosity, 540
REM. See Rapid eye movement
Renneberg, B., 583
Research Diagnostic Criteria (RDC), 17, 366
Research Domain Criteria (RDoC), 28
Research Scale for the Assessment of Psychopathy. See Psychopathy Checklist
Response modulation hypothesis (RMH), 629–632, 637
Response styles theory (RST), 279
Restless legs syndrome (RLS), 382
Restrictive behaviors, 469, 484
Retrograde ejaculation, 543
Revised Diagnostic Interview for Borderlines (DIB-R), 586–587
Revised NEO Personality Inventory (NEO PI-R), 588
Reward sensitivity, 333–334
Rhee, S. H., 632, 633
Rice, M. E., 635
Rietschel, M., 547
Riggs, D. S., 232, 238
Rimm, T., 572–573, 574, 592
Riso, L. P., 282
Risperidone
for bipolar disorder, 338
for borderline personality disorder, 593
for posttraumatic stress disorder, 244
for social anxiety disorder, 65
Rituals, 190, 204
RLS. See Restless legs syndrome
RMH. See Response modulation hypothesis
Robins, E., 4, 5, 6, 24
Rodebaugh, T. L., 59–60
Rodke, G., 553
Rodrique, S., 373
Roelofs, J., 281
Rogosch, F. A., 572
Rogers, B. E., 342
Rogers, T., 572–573
Rogers, T., 572
Rohde, L., 206
Rohde, L., 281
Rosenthal, N. E., 331
Rosen, R. C., 534
Rosen, R. C., 534
Rosen, R. C., 534, 547
Rosenfield, D., 119, 635
Roth, T., 382
Rosen, R. C., 534
Rosenhan, D. L., 11
Rothschild, L., 586
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Roth, T., 382
Rothschild, L., 586
Sexual dysfunctions (Continued)
sexual pain disorders, genito-pelvic
pain/penetration disorder, 549–554
summary and future directions, 554
Sexual guilt, 540
Sexual pain disorders, 549–554
Sexual tipping point model, 534
SF-36. See 36-Item Short Form Health
Survey
SFT. See Schema-focused therapy
Shapiro, J. R., 492
Shnaider, P., 241
SIAS. See Social Interaction Anxiety Scale
Sickle-cell anemia, 3
SIDP-IV. See Structured Interview for
DSM-IV Personality Disorders
Sigman, M., 99
Sildenafil, 527, 528, 534–536
Silk, K. R., 567
Simeon, A. E., 27
Simon, G. E., 340–341
Simonsen, E., 222
Sin, sex as, 540
Singer, M., 565
Single nucleotide polymorphisms (SNPs), 283, 453
Single-photon emission computed
tomography (SPECT), 199, 328,
484–485
Sinoatrial node (SA), 107n2
SIPS. See Structured Interview for Prodromal
Syndromes
Sisk, C. L., 489
SIT. See Stress-Inoculation Therapy
Situationally accessible memories (SAM), 227
Skeem, J. L., 636
Skinner, B. F., 270
Skinner, H. A., 6
Skodol, A. E., 27
Sleep, 331–332
Sleep diary, 375–376
Sleep hygiene, 377
Sleep onset latency (SOL), 374
Sleep quality (SQ), 374
Sleep restriction therapy, 377
Sleep-wake disorders
assessment, 373
assessment of subjectively perceived
sleep, 374–376
clinical interview, 374
objective estimates, 376
case examples
insomnia with comorbidity, 366–367
insomnia without comorbidity, 366
circadian rhythm disorder, 382–383
comorbidity, 384–385
description, symptoms and criteria,
365–366
in DSM-5, 366
emotion, role of, 372–373
environmental factors, 373–374
epidemiology, 368–369
gender differences, 368
history of insomnia, 367–368
hypersomnia, 383
interventions
for children and adolescents, 383–384
cognitive-behavioral therapy for
insomnia, 376–378
pharmacological interventions, 380–381
psychological vs. pharmacological
interventions, 381–383
treatment adherence, 379
treatment of comorbid insomnia, 379–380
models of insomnia
behavioral stimulus control model, 369
cognitive model, 369–370
homeostatic and circadian influences,
372
hybrid models, 371–372
hyperarousal models, 370
neurocognitive model, 370–371
three-factor model, 369
narcolepsy, 383
periodic limb movement disorder, 382
restless legs syndrome, 382
sleep across development, 365
sleep apnea, 382
sleep basics, 364–365
SLT. See Social learning theory
SMART. See Self-Management and
Recovery Training
Smith, Bob, 430
Smith, K., 241
Smith, L., 573
Smith, M. T., 380
Smith, S. S., 622
Smoking, 435
Smooth muscle relaxation, 535, 536
Smooth pursuit eye movement dysfunction,
29
SNAP. See Schedule for Nonadaptive and
Adaptive Personality
SNAP-2. See Schedule for Nonadaptive and
Adaptive Personality—Second Edition
SNPs. See Single nucleotide polymorphisms
SNRI. See Serotonin-norepinephrine
reuptake inhibitors
SNS. See Sympathetic nervous system
Snyder, K. S., 330
Social anxiety disorder (SAD)
assessment
clinical interviews, 58
clinical rating scales, 58–59
neurobiological, 61
self-report measures, 59–60
session-by-session, 60–61
biological factors, 45–47
cognitive-behavioral model of, 47–49,
62–64
comorbidity with, 42–45
cultural rates, 41–42
description of, 39–42
in DSM-5, 39–40
environmental and sociocultural factors,
55–57
genetics, 45–46
internet-based interventions, 67
with major depressive disorder, 42–43
neurobiology, 46–47
prevalence and epidemiological factors,
41–45
psychological and psychosocial
dysfunction
attentional bias, 49–51
employment impairment, 41
judgment and interpretation bias, 51–53
memory and imagery bias, 53–55
panic attacks, 39
safety behaviors, 40–41, 62
substance use with, 43–44
summary and future directions, 66–67
symptoms and criteria, 39–41
treatment
biological interventions, 46, 47, 64–66
psychological interventions, 44, 47,
61–64
Social Anxiety Session Change Index
Social cognition, 395, 401–402, 583–585
Social Interaction Anxiety Scale (SIAS),
59–60
Social learning theory (SLT), 445–446
Social phobia, 20
Social Phobia and Anxiety Inventory (SPAI),
59, 60
Social Phobia Inventory (SPIN), 60
Social Phobia Scale (SPS), 59
Society of Obstetricians and Gynaecologists
of Canada, Clinical Practice
Gynaecology Committee and Ethics
Committee, 539–540
Sociopathy, 614–615
SOL. See Sleep onset latency
Soldier’s heart, 87
Somatic arousal, 370
Sommerfield, C., 239
Sonnen, A., 220
Sood, R., 381–382
Southwick, S. M., 224
SPAI. See Social Phobia and Anxiety
Inventory
Spangler, D., 282
Specialist supported individual therapy
(SRIT), 496
Specifiers, 265–266
SPECT. See Single-photon emission
computed tomography
Spectatoring, 534
Spielman, A. J., 369, 377
SPIN. See Social Phobia Inventory
Spinal cord, injury to, 543
Spitzer, R. L., 11, 565
Sprengelmeyer, R., 585
SPS. See Social Phobia Scale
SQ. See Sleep quality
Squeeze technique, 548
SRD. See Stress-response dampening
SRP. See Self-Report Psychopathy scale
SRIT. See Specialist supported individual
therapy
Uncertainty, intolerance of, 161–162
Unconditioned stimulus (UCS), 627
Unipolar mania, 319
Unutzer, J., 340–341
Urological chronic pelvic pain syndrome (UCPPS), 550
Vagal tone, 107, 107n2
Vaginismus, 549, 550, 551, 552, 554
Vaginoplasty, 539
Vagus nerve, 539
Vaiva, G., 225
Valdoxan. See Agomelatine
Valentine, J. D., 233
Valentiner, D. P., 157
Validity, 4–7, 8, 10
VAM. See Verbally accessible memories
van Praag, Herman, 23–24
Vancouver Obsessive Compulsive Inventory (VOCI), 201
Vardenafil hydrochloride, 527
Vascular disease, 533–534, 535, 539
Vasoactive gels, 536
Veague, H. B., 584
Veen, G., 585
Venlafaxine
for generalized anxiety disorder, 155, 173
for posttraumatic stress disorder, 243
for social anxiety disorder, 64, 65
Ventromedial prefrontal cortex (vmPFC) with bipolar disorder, 329
with generalized anxiety disorder, 155
with panic disorder, 105, 124
Verbally accessible memories (VAM), 227
Vestergren, E., 485
Vestibularectomy, 553
Vietnam Era Twin Registry, 103
Virtual reality exposure, 245
Vivitol, 451
vmPFC. See Ventromedial prefrontal cortex
VOI., 370
VOCI. See Vancouver Obsessive Compulsive Inventory
Vogel, P. A., 209
Vogt, D., 211
Vulvodynia, 551
Vulvovaginal atrophy, 527, 551
Wachen, J. S., 241
Wakefield, J. C., 7, 14, 23
Wakefulness after sleep onset (WASO), 366
Waldinger, M. D., 543, 547
Waldman, I. D., 632, 633
Wallace, J. F., 636
Wallin, U., 492
Walter, K. H., 230–231
Wang, S., 224
Warren, C. S., 473
Washington University K-SADS, 335
WASO. See Total amount of time awake after sleep onset; Wakefulness after sleep onset
Watt, M. C., 109
Watts, B. V., 243
WCST. See Wisconsin Card Sorting Task
WDQ. See Worry Domains Questionnaire
Weaver, T. L., 239
Weeks, J. W., 48
Wehr, T. A., 331
Weight phobia, 465, 467, 468–469, 470
Wellbutrin. See Bupropion
Wells, A., 49, 162–163, 171
Wenzel, A., 53
Werbie, B., 565
Werner, K., 46
Westenberg, H. G., 572–573
Westoxetin. See Dapoxetine
WFSBP. See World Federation of Societies of Biological Psychiatry
Whaley, S. E., 99
White, M. A., 499
White, W. C., 472
WHO. See World Health Organization
Why Worry Scale, 169
Why Worry Scale-II, 169
Widiger, T. A., 216, 222, 623
Wiegel, M., 528
Wilhelm, S., 209
Will, George, 9
Williams, K. M., 624
Wilsnack, R. W., 438–439
Wilson, Bill, 430
Wilson, G. T., 473, 499
Wilson, K. G., 172
Wincicott, D. W., 568
Wisconsin Card Sorting Task (WCST), 582
Wise, R. A., 447
Witkiewitz, K., 446
Wolff, H. G., 476
Wong, J. 48
Wong, S., 635
Wood, J., 99
Wood, J. M., 377
Woods, C. M., 59–60
Woolson, S. L., 492
Woon, F. L., 226
World Federation of Societies of Biological Psychiatry (WFSBP), 502
World Health Organization (WHO), 321, 436, 538
World Mental Health Survey, 269, 321
Worry, 149–150, 157–158, 162–164
Worry Domains Questionnaire (WDQ), 168
Wouters, L., 592
Wu, K. D., 157
Yale-Brown Obsessive Compulsive Scale (Y-BOCS), 200
Yarczower, M., 232
Y-BOCS. See Yale-Brown Obsessive Compulsive Scale
Yehuda, R., 224
Young, A., 585
Young, A. W., 553
Youth Psychopathic Traits Inventory (YPI), 621, 632
YPI-Child Version (YPI-CV), 621
Zahner, G. E. P., 99
Zanarini, M. C., 562, 567, 590, 591, 593
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD), 587–588
Zeier, J. D., 631
Zielezny, M., 117
Zimmerman, M., 44, 567, 586
Ziprasidone, 338
Zoloft. See Sertraline
Zopiclone, 381
Zucker, R. A., 443